1. Home
  2. AMIX vs VIRX Comparison

AMIX vs VIRX Comparison

Compare AMIX & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMIX
  • VIRX
  • Stock Information
  • Founded
  • AMIX 2014
  • VIRX 2007
  • Country
  • AMIX United States
  • VIRX United States
  • Employees
  • AMIX N/A
  • VIRX N/A
  • Industry
  • AMIX
  • VIRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMIX
  • VIRX Health Care
  • Exchange
  • AMIX NYSE
  • VIRX Nasdaq
  • Market Cap
  • AMIX 8.9M
  • VIRX 7.7M
  • IPO Year
  • AMIX N/A
  • VIRX N/A
  • Fundamental
  • Price
  • AMIX $6.35
  • VIRX $0.16
  • Analyst Decision
  • AMIX
  • VIRX Buy
  • Analyst Count
  • AMIX 0
  • VIRX 4
  • Target Price
  • AMIX N/A
  • VIRX $5.00
  • AVG Volume (30 Days)
  • AMIX 1.5M
  • VIRX 2.7M
  • Earning Date
  • AMIX 11-11-2024
  • VIRX 11-13-2024
  • Dividend Yield
  • AMIX N/A
  • VIRX N/A
  • EPS Growth
  • AMIX N/A
  • VIRX N/A
  • EPS
  • AMIX N/A
  • VIRX N/A
  • Revenue
  • AMIX N/A
  • VIRX N/A
  • Revenue This Year
  • AMIX N/A
  • VIRX N/A
  • Revenue Next Year
  • AMIX N/A
  • VIRX N/A
  • P/E Ratio
  • AMIX N/A
  • VIRX N/A
  • Revenue Growth
  • AMIX N/A
  • VIRX N/A
  • 52 Week Low
  • AMIX $7.51
  • VIRX $0.13
  • 52 Week High
  • AMIX $152.00
  • VIRX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • AMIX 57.64
  • VIRX 23.87
  • Support Level
  • AMIX $11.70
  • VIRX $0.14
  • Resistance Level
  • AMIX $13.78
  • VIRX $0.21
  • Average True Range (ATR)
  • AMIX 1.70
  • VIRX 0.01
  • MACD
  • AMIX 0.34
  • VIRX -0.00
  • Stochastic Oscillator
  • AMIX 75.21
  • VIRX 31.14

About AMIX AUTONOMIX MEDICAL INC

Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Share on Social Networks: